Veliparib With or Without Carboplatin in Treating Patients With Stage III-IV Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/9/2019 |
Start Date: | June 30, 2010 |
Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer
This phase II trial studies how well veliparib with or without carboplatin works in treating
patients with stage III-IV breast cancer. Veliparib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether veliparib is more effective with or without carboplatin in treating breast
cancer.
patients with stage III-IV breast cancer. Veliparib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether veliparib is more effective with or without carboplatin in treating breast
cancer.
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of single agent ABT-888 (veliparib) (NSC 737664) in breast cancer
(BRCA) carriers with metastatic breast cancer based on response rate (Response Evaluation
Criteria In Solid Tumors [RECIST] criteria).
SECONDARY OBJECTIVES:
I. To conduct subset analysis on BRCA1 vs. BRCA2 and hormone receptor status. II. To evaluate
progression-free survival of patients on single-agent ABT-888. III. To further describe the
safety and tolerability of ABT-888 (NSC 737664) as a single agent and in combination with
carboplatin for BRCA-associated breast cancer.
IV. To evaluate the pharmacokinetics of ABT-888 (NSC 737664) alone and in combination with
carboplatin.
V. To assess the relationship between the level of poly adenosine diphosphate (ADP) ribose
polymerase (PARP) inhibition by ABT-888 and biomarkers of deoxyribonucleic acid (DNA) damage
in peripheral blood mononuclear cell (PBMC's) and in tumor.
VI. To explore the relationship between biomarkers of drug effect and progression-free
survival.
VII. To evaluate the efficacy and safety of the combination of carboplatin and ABT-888 in
patients who have failed single agent ABT-888.
VIII. To conduct subset analysis on BRCA1 vs. BRCA2 and hormone receptor status.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive veliparib orally (PO) twice daily (BID) on days 1-21.
ARM II: Patients receive carboplatin intravenously (IV) over 30 minutes on day 1 and
veliparib as in Arm I.
In both arms, treatment repeats every 21 days in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3-6 months.
I. To evaluate the efficacy of single agent ABT-888 (veliparib) (NSC 737664) in breast cancer
(BRCA) carriers with metastatic breast cancer based on response rate (Response Evaluation
Criteria In Solid Tumors [RECIST] criteria).
SECONDARY OBJECTIVES:
I. To conduct subset analysis on BRCA1 vs. BRCA2 and hormone receptor status. II. To evaluate
progression-free survival of patients on single-agent ABT-888. III. To further describe the
safety and tolerability of ABT-888 (NSC 737664) as a single agent and in combination with
carboplatin for BRCA-associated breast cancer.
IV. To evaluate the pharmacokinetics of ABT-888 (NSC 737664) alone and in combination with
carboplatin.
V. To assess the relationship between the level of poly adenosine diphosphate (ADP) ribose
polymerase (PARP) inhibition by ABT-888 and biomarkers of deoxyribonucleic acid (DNA) damage
in peripheral blood mononuclear cell (PBMC's) and in tumor.
VI. To explore the relationship between biomarkers of drug effect and progression-free
survival.
VII. To evaluate the efficacy and safety of the combination of carboplatin and ABT-888 in
patients who have failed single agent ABT-888.
VIII. To conduct subset analysis on BRCA1 vs. BRCA2 and hormone receptor status.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive veliparib orally (PO) twice daily (BID) on days 1-21.
ARM II: Patients receive carboplatin intravenously (IV) over 30 minutes on day 1 and
veliparib as in Arm I.
In both arms, treatment repeats every 21 days in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3-6 months.
Inclusion Criteria:
- Patients must be female, and must have histologically confirmed breast cancer that is
metastatic or locally advanced, unresectable and for which standard curative measures
do not exist or are no longer effective
- Patient must have a known deleterious BRCA mutation confirmed by report from a
Clinical Laboratory Improvement Amendments (CLIA) certified laboratory (generally
Myriad Genetics Laboratory)
- Measurable disease by RECIST criteria; (evaluable disease is allowed only for the
safety lead-in phase)
- Prior chemotherapy regimens for metastatic disease are completed, at least 3 weeks
prior to starting therapy; prior radiation and hormonal treatment must be completed at
least 1 week prior to starting therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Life expectancy greater than four months
- Absolute neutrophil count (ANC) >= 1,500/mcL
- Platelet count >= 100,000/mcL
- Total bilirubin =< 1.5 times institutional upper limit of normal
- Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) and
alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) =< 2.5
times institutional upper limit of normal unless there is evidence of liver
metastasis, in which case the AST (SGOT)/ALT (SGPT) must be =< 5 times institutional
upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60
mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- If a woman is of child-bearing potential, a negative serum or urine pregnancy test is
required; women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to study
entry and for the duration of study participation; participants should agree to use
contraception for at least 3 months after the completion of study therapy; should a
woman become pregnant or suspect she is pregnant while participating in this study,
she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Prior therapy with platinum agents (adjuvant therapy with platinum agents is allowed,
if completed >= 12 months prior to relapse), or PARP inhibitors (prior iniparib, since
it is no longer considered a PARP inhibitor, is allowed)
- Patients may not be receiving any other investigational agents
- Patients with known central nervous system (CNS) metastases requiring anticonvulsive
medications, or steroids or with active symptomatology; patients on anticonvulsant
medications prescribed for reasons other than CNS metastases, not on steroids and
without active symptomatology are eligible; patients must be off anti-seizure
medications and steroids for 3 months or more before enrollment
- Patients with active seizure or a history of seizure; patients with CNS metastases
must be stable after therapy for > 3 months and off steroid treatment prior to study
enrollment
- History of allergic reactions attributed to compounds of similar chemical or
biological composition to ABT-888 (NSC 737664) or PARP Inhibitors
- Patients with contraindications to platinum agents are excluded
- Prior or current non-breast malignancy within 5 years except non-melanoma skin cancer
or resected stage I ovarian cancer
- Patients with any non-malignant intercurrent illness (e.g., cardiovascular, pulmonary,
or central nervous system disease) which is either poorly controlled with currently
available treatment or which is of such severity that the investigators deem it unwise
to enter the patient on protocol
- Pregnant women are excluded from this study; breastfeeding should be discontinued
- Patients unable to swallow the ABT-888 tablets whole are ineligible; (the tablets
cannot be crushed or broken)
- Patients with an active severe infection; known infection with human immunodeficiency
virus (HIV), hepatitis B virus, or hepatitis C virus; HIV patients on combination
antiretroviral therapy are ineligible
We found this trial at
23
sites
Click here to add this to my saved trials
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
Click here to add this to my saved trials
Click here to add this to my saved trials
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials